

Supplemental Figures for:

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From the SystHERs Registry

Debu Tripathy et al.

Figure S1. (A) Progression-free survival and (B) overall survival in patients with recurrent disease and EBC to MBC diagnosis durations of <24 vs ≥24 months

CI, confidence interval; EBC, early breast cancer; MBC, metastatic breast cancer; NE, not evaluable; OS, overall survival; PFS, progression-free survival.



